Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.52 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 8/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12112017 | 1.00 | SPHK1 (0.52) | SPHK1SPHK2FAAHMGLLPTGER2 | |
| SCHEMBL12621415 | 0.90 | FAAH (0.50) | SPHK1SPHK2FAAHMGLLPTGER2 | |
| SCHEMBL13693307 | 0.81 | FAAH (0.49) | SPHK1FAAHMGLLPTGER2PTGER3 | |
| SCHEMBL12568629 | 0.81 | FAAH (0.49) | SPHK1FAAHMGLLPTGER2PTGER3 | |
| SCHEMBL14444576 | 0.81 | FAAH (0.49) | SPHK1FAAHMGLLPTGER2PTGER3 | |
| SCHEMBL15574686 | 0.80 | PTGER2 (0.41) | SPHK1SPHK2PTGER2PTGER3PTGDR | |
| SCHEMBL13693092 | 0.80 | PTGER2 (0.65) | PTGER2PTGER3PTGDRPTGER1PTGER4 | |
| SCHEMBL19144203 | 0.80 | PTGER2 (0.65) | PTGER2PTGER3PTGDRPTGER1PTGER4 | |
| SCHEMBL15491993 | 0.79 | PTGER2 (0.53) | PTGER2PTGER3PTGDRPTGER1PTGER4 | |
| SCHEMBL13747015 | 0.79 | FAAH (0.47) | SPHK1FAAHMGLLPTGER2PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121672-B1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2014-12-10 | — | — | EP | disclosed |
| US-8377984-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377984-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-7960381-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960381-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100093729-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093729-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2009097223-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20090192159-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090192159-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2009-07-30 | — | — | US | disclosed |
| WO-2008094912-A2 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093729-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | SPHK1 2455/4885SPHK2 2505/4885FAAH 3019/4885 |
| US-20090192159-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, B3GAT3, TGM1 | SPHK1 3618/4885SPHK2 3808/4885FAAH 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.